EmpressTX offers the Chemilogics™ platform, which uses human genetic data, AI/ML, and co‑evolutionary algorithms to generate drug‑like small molecules that are naturally encoded in the genome. By predicting and prioritizing millions of chemically diverse candidates and enabling rapid synthetic‑biology production, the platform reduces lead‑identification timelines from years to months, providing pharmaceutical and biotech companies with biologically validated starting points for drug development.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery relies on random chemical libraries and lengthy synthesis cycles, leading to high costs and multi‑year timelines with low success rates. Access to novel, biologically relevant starting points is limited, slowing the development of effective therapeutics.
Solution
EmpressTX addresses these challenges with its Chemilogics™ platform, which leverages human genetic data, artificial intelligence, and co‑evolutionary principles to generate drug‑like small molecules that are already encoded in the human genome. By identifying compounds that have been naturally selected through evolution, the platform provides chemically tractable starting points with a higher likelihood of biological relevance. AI/ML models predict and prioritize millions of candidate structures, while synthetic biology techniques enable rapid production of these molecules. The end‑to‑end workflow reduces the lead‑identification phase from years to months, delivering a scalable pipeline of novel chemistries for downstream development.
Target Audience
Primary customers are pharmaceutical companies, biotechnology firms, and academic research groups seeking accelerated lead generation and access to genetically validated chemical space for therapeutic programs.
Features
- Integration of human genetic variant data to discover small molecules naturally encoded in the genome
- AI/ML-driven design and prioritization of millions of chemically diverse candidates
- Co‑evolutionary selection algorithms that favor biologically validated scaffolds
- Synthetic biology manufacturing pipeline for fast, on‑demand synthesis of predicted compounds
- Rapid turnaround time, delivering viable starting points within months rather than years
- Platform‑agnostic output compatible with standard medicinal chemistry and high‑throughput screening workflows